Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI
Memantine to Preserve Memory and Neurocognition Following Craniospinal Irradiation- A Randomised Controlled Trial (MEMENTO)
Tata Memorial Centre
101 participants
Feb 22, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.
Eligibility
Inclusion Criteria4
- Age at irradiation: 5 to 39 years
- Planned for CSI (with or without boost dose) with or without systemic chemotherapy
- Informed consent or assent taken
- Karnofsky Performance Status / Lansky Performance Status ≥ 60
Exclusion Criteria3
- Re-irradiation
- Prior exposure to memantine
- Inability to undergo Wechsler test
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Drug to preserve memory and neurocognitive dysfunction induced by radiation therapy
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06275035